Pharmacology · Adrenergic Pharmacology

Beta-Adrenergic Antagonists

Classification by generation, HFrEF-approved agents, adverse effects, and key drug interactions

Beta-blockers are classified by generation: first-generation agents (propranolol, nadolol, timolol) are non-selective, blocking beta-1 and beta-2 equally, with risk of bronchoconstriction and peripheral vasoconstriction; second-generation agents (metoprolol, atenolol, bisoprolol) are cardioselective, preferentially blocking beta-1 at standard doses — but selectivity is dose-dependent, and asthma is an absolute contraindication for all beta-blockers regardless of generation.
Third-generation beta-blockers combine beta-blockade with vasodilation: carvedilol and labetalol add alpha-1 blockade (reducing peripheral vascular resistance), while nebivolol at higher doses generates nitric oxide-mediated vasodilation — the result is blood pressure reduction through both reduced cardiac output and reduced peripheral resistance, without the reflex tachycardia seen with pure vasodilators.
Only three beta-blockers have proven mortality benefit in heart failure with reduced ejection fraction (HFrEF): carvedilol, bisoprolol, and metoprolol succinate (extended-release) — these agents reverse sympathetic remodeling and improve ejection fraction over months, but must be started only when the patient is euvolemic and hemodynamically stable, never during acute decompensation.
The most dangerous adverse effect is abrupt withdrawal: upregulated beta-1 receptors from chronic blockade respond to catecholamine surge, causing rebound tachycardia, hypertension, and myocardial infarction risk in coronary artery disease — always taper over one to two weeks. In metabolic terms, beta-blockers mask the tachycardia warning sign of hypoglycemia (sweating is preserved) and non-selective agents additionally prolong hypoglycemia.
The most critical drug interaction is intravenous verapamil or diltiazem combined with a beta-blocker, which can cause fatal AV block or asystole through additive nodal depression — this combination is absolutely contraindicated intravenously. Epinephrine given to a patient on a non-selective beta-blocker causes unopposed alpha-1 vasoconstriction and paradoxical severe hypertension; glucagon is the rescue agent in this setting.

Abbreviations: HFrEF = heart failure with reduced ejection fraction · AV = atrioventricular · COPD = chronic obstructive pulmonary disease · ISA = intrinsic sympathomimetic activity · NSAID = nonsteroidal anti-inflammatory drug · CAD = coronary artery disease

Classification by Generation and Selectivity

First Generation

Non-Selective

BlocksBeta-1 AND beta-2 receptors equally

DrugsPropranolol, nadolol, timolol

Beta-2 SEBronchoconstriction, peripheral vasoconstriction

PropranololThyroid storm (also inhibits T4→T3 conversion); essential tremor; migraine prophylaxis

Second Generation

Cardioselective (Beta-1)

BlocksBeta-1 preferentially; spares beta-2 at standard doses

DrugsMetoprolol, atenolol, bisoprolol

BenefitLess bronchoconstriction and peripheral vasoconstriction

NoteSelectivity is dose-dependent. Asthma still contraindicated.

Third Generation

Vasodilatory

CarvedilolBeta-1/2 + alpha-1 blockade → vasodilation; HFrEF (approved); take with food

LabetalolBeta-1/2 + alpha-1 blockade; hypertensive emergency; drug of choice in pregnancy

BenefitReduces cardiac output AND peripheral vascular resistance; no reflex tachycardia

HFrEF-Approved Agents

Three Only

AgentsCarvedilol, bisoprolol, metoprolol succinate (extended-release) ONLY

MechanismReverse sympathetic remodeling → receptor resensitization → improved ejection fraction over months

RuleStart ONLY when euvolemic and stable. Never during acute decompensation. Start low, double every 2 weeks.

Adverse Effects & Absolute Contraindications

Cardiac

Bradycardia, AV block. Contraindicated: Mobitz II or 3rd-degree AV block, sick sinus syndrome (without pacemaker), cardiogenic shock.

Pulmonary

Bronchospasm from beta-2 blockade. Contraindicated: Asthma — ALL beta-blockers including cardioselective agents. COPD without reversibility is relative.

Metabolic

Masks hypoglycemia (tachycardia blunted; sweating preserved). Non-selective agents also raise triglycerides. Use cardioselective in diabetes.

Withdrawal

Never stop abruptly. Taper over 1–2 weeks. Rebound tachycardia, angina, and myocardial infarction risk in CAD patients.

Key Drug Interactions

Interacting Drug	Consequence and Management
Verapamil / Diltiazem (intravenous)	Severe AV block, asystole. Never give intravenous verapamil to a patient on a beta-blocker. Use with extreme caution even orally.
Epinephrine (with non-selective beta-blocker)	Beta-2 vasodilation blocked → unopposed alpha-1 vasoconstriction → severe hypertension. Risk in anaphylaxis on propranolol — use glucagon.
Insulin / sulfonylureas	Hypoglycemia warning signs masked (tachycardia, tremor). Sweating preserved. Non-selective agents also prolong hypoglycemia. Use cardioselective agents.
NSAIDs	Blunt antihypertensive efficacy through prostaglandin-mediated sodium retention. Monitor blood pressure when NSAIDs added.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Westfall TC, Westfall DP	Adrenergic agonists and antagonists. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th ed.	McGraw-Hill, 2018:191–224
Frishman WH	Beta-adrenergic receptor blockers: adverse effects and drug interactions	Hypertension. 1988;11(3 Pt 2):II21–II29
Frishman WH	Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties	Am Heart J. 1979;97(5):663–670
MERIT-HF Study Group	Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF)	Lancet. 1999;353(9169):2001–2007
Cleland JG, Bristow MR, Erdmann E, et al	Beta-blocking agents in heart failure. Should they be used and how?	Eur Heart J. 1996;17(11):1629–1639
CIBIS-II Investigators and Committees	The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial	Lancet. 1999;353(9146):9–13
Wiysonge CS, Bradley HA, Volmink J, et al	Beta-blockers for hypertension	Cochrane Database Syst Rev. 2017;1(1):CD002003
Echt DS, Liebson PR, Mitchell LB, et al	Mortality and morbidity in patients receiving encainide, flecainide, or placebo (CAST)	N Engl J Med. 1991;324(12):781–788
Packer M, Bristow MR, Cohn JN, et al	The effect of carvedilol on morbidity and mortality in patients with chronic heart failure	N Engl J Med. 1996;334(21):1349–1355
Magee LA, Cham C, Waterman EJ, et al	Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis	BMJ. 2003;327(7421):955–960
Johnson JA, Burlew BS	Metoprolol metabolism via cytochrome P4502D6 in ethnic populations	Drug Metab Dispos. 1996;24(3):350–355